Literature DB >> 33814802

Role of Cervical Cancer Biomarkers p16 and Ki67 in Abnormal Cervical Cytological Smear.

Meenakshi Gothwal1, Aasma Nalwa2, Pratibha Singh1, Garima Yadav1, Meenal Bhati1, Nitesh Samriya3.   

Abstract

INTRODUCTION: Cervical cancer is the most common cancer in India. Screening for cervical cancer helps in marked reduction of invasive cervical cancers. The low sensitivity of Papanicolaou cytology (Pap smear) and high-risk human papillomavirus (HR-HPV) in excluding high-grade intraepithelial lesion (ASC-H) leads to unnecessary referrals to colposcopy-guided biopsy. The combined cervical cytology screening and HR-HPV have its own limitations and still need further standardization. Using additional biomarkers like staining with p16 and Ki-67 might help in triaging abnormal pap smear.
MATERIALS AND METHODS: A prospective, cross-sectional study was performed over a period of 16 months in the Department of Obstetrics and Gynaecology, in collaboration with Department of Pathology. Study was conducted to know the efficacy of immunostaining with p16/Ki-67 in predicting the presence of significant lesion in cases of mild cytological atypia. PAP smears (conventional and LBC) along with P16, Ki-67 and available biopsies were correlated.
RESULTS: Liquid-based cytology (LBC) was done in 2134 cases, out of which 46 cases showed abnormal cytological findings such as [22 atypical squamous cells of undetermined significance (ASCUS), 3 low-grade squamous intraepithelial lesion (LSIL), 8 atypical squamous cells cannot exclude high-grade lesion (ASC-H), 6 high-grade squamous intraepithelial lesion (HSIL), 5 squamous cell carcinoma (SCC), 2 adenocarcinoma, 1 atypical glandular cells of undetermined significance (AGUS)]. Immunostaining with p16 and Ki-67 was performed on 38 cases of abnormal cytological smears. Out of 38 abnormal cytology cases, 28 cases had shown co-staining for both p16 and Ki-67, suggestive of true HPV infection of the cells. Of the 38 cases, 07/14 ASCUS, 06/06 HSIL, 07/08 ASC-H, 05/05 squamous cell carcinoma and 02/02 adenocarcinoma also showed dual positivity for p16 and Ki-67. One case of AGUS was diagnosed, but the smear was unsatisfactory for immunocytochemical evaluation and excluded from the study. Three cases of LSIL were also diagnosed on cytological evaluation, and 1 of them however showed positivity for p16 and Ki-67 on immunocytochemistry (ICC). In the ASC-US group, the sensitivity and specificity of the immunostaining in diagnosing CIN2 + lesions were 87.51%, and in LSIL group, the sensitivity and specificity of the immunostaining in diagnosing CIN2 + lesions were 100%. p16/Ki-67 positivity also increased with cytological severity which in turn corresponded with histological findings: it reached from 50% in ASC-US to 100% in both HSIL and SCC categories.
CONCLUSION: This immunostaining with p16 and Ki67 can be a useful method in the triaging of the ASC-US and the LSIL group as considering the high sensitivity and specificity values. © Federation of Obstetric & Gynecological Societies of India 2020.

Entities:  

Keywords:  ASC-US; ICC; Ki67; Liquid-based cytology; p16

Year:  2020        PMID: 33814802      PMCID: PMC7960869          DOI: 10.1007/s13224-020-01380-y

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  11 in total

1.  Quality management in gynecologic cytology using interlaboratory comparison.

Authors:  B A Jones; D D Davey
Journal:  Arch Pathol Lab Med       Date:  2000-05       Impact factor: 5.534

2.  Utility of P16 expression and Ki-67 proliferation index in ASCUS and ASC-H pap tests.

Authors:  Adam D Toll; Deidra Kelly; Zahra Maleki
Journal:  Diagn Cytopathol       Date:  2013-11-28       Impact factor: 1.582

3.  Evaluation of CINtec PLUS® testing as an adjunctive test in ASC-US diagnosed SurePath® preparations.

Authors:  Neil Edgerton; Cynthia Cohen; Momin T Siddiqui
Journal:  Diagn Cytopathol       Date:  2011-06-27       Impact factor: 1.582

4.  Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.

Authors:  K Ulrich Petry; Dietmar Schmidt; Sarah Scherbring; Alexander Luyten; Axel Reinecke-Lüthge; Christine Bergeron; Friedrich Kommoss; Thomas Löning; Jaume Ordi; Sigrid Regauer; Ruediger Ridder
Journal:  Gynecol Oncol       Date:  2011-03-21       Impact factor: 5.482

5.  Improved abnormal Pap smear triage using cervical cancer biomarkers.

Authors:  Jeffrey L Killeen; Timothy Dye; Chelestes Grace; Mark Hiraoka
Journal:  J Low Genit Tract Dis       Date:  2014-01       Impact factor: 1.925

6.  Meta-analysis on the performance of p16/Ki-67 dual immunostaining in detecting high-grade cervical intraepithelial neoplasm.

Authors:  Meng Sun; Yang Shen; Mu-Lan Ren; Yi-Min Dong
Journal:  J Cancer Res Ther       Date:  2018-09       Impact factor: 1.805

7.  Immunostaining of p16(INK4a)/Ki-67 and L1 capsid protein on liquid-based cytology specimens obtained from ASC-H and LSIL-H cases.

Authors:  Seung Won Byun; Ahwon Lee; Suyeon Kim; Yeong Jin Choi; Youn Soo Lee; Jong Sup Park
Journal:  Int J Med Sci       Date:  2013-09-12       Impact factor: 3.738

8.  The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL.

Authors:  Júlio C Possati-Resende; José H T G Fregnani; Ligia M Kerr; Edmundo C Mauad; Adhemar Longatto-Filho; Cristovam Scapulatempo-Neto
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

Review 9.  Papillomavirus life cycle organization and biomarker selection.

Authors:  John Doorbar
Journal:  Dis Markers       Date:  2007       Impact factor: 3.434

10.  Role of p16/Ki-67 Dual Immunostaining in Detection of Cervical Cancer Precursors.

Authors:  Diya Das; Moumita Sengupta; Keya Basu; Mona Tirkey; Chhanda Datta; Uttara Chatterjee
Journal:  J Cytol       Date:  2018 Jul-Sep       Impact factor: 1.000

View more
  1 in total

1.  Study on the correlation between energy spectrum computed tomography imaging and the pathological characteristics and prognosis of cervical cancer.

Authors:  Libo Pan; Xia Jia; Xuewu Zhao; Bei Zhang; Shusheng Wang; Tao Fan; Min Zhou; Yuan Yuan; Guoqing Wang; Longmei Xue
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.